Abstract：
UNASSIGNED: Angioimmunoblastic T-cell lymphoma (AITL) is one of the sub-types of peripheral T-cell lymphomas (PTCLs) that are remarkably refractory and has the potential to have a poor prognosis. The treatment process includes a wide range of treatment modalities, from anthracycline-based regimens that have been used for years to novel agents, such as histone deacetylase inhibitor romidepsin and belinostat. Increased treatment response rates and prolonged survival have been reported in studies with belinostat. Similarly, in this case report, we wanted to share a patient of an advanced age and with a high IPI score, whom we had treated in many treatment lines and maintained a long-term treatment response by administering belinostat.
摘要：
血管免疫母细胞性T细胞淋巴瘤（AITL）是外周T细胞淋巴瘤（PTCL）的亚型之一，其非常难治并有可能预后不良。治疗过程包括广泛的治疗方式，从使用多年的蒽环类药物到新型药物，如组蛋白去乙酰化酶抑制剂romidepsin和belinostat。在使用belinostat的研究中已经报道了增加的治疗反应率和延长的生存期。同样，在这个案例报告中,我们想分享一位高龄患者，IPI评分高，我们曾在许多治疗系列中对其进行过治疗，并通过服用belinostat维持了长期治疗反应。
